



HAWAI'I STATE DEPARTMENT OF HEALTH

Outpatient Oral COVID-19 Treatments for Medical Providers

Patients who test positive for COVID-19 with any test (home or clinic) [may be eligible](#) for Paxlovid or Molnupiravir if they are at high risk of severe illness.

Treatment

- » Should begin ASAP and within 5 days of symptom onset
- » Can be e-prescribed
- » Not for hospitalized patients
- » Available at many pharmacies and hospitals ([Locations listed here](#))

High risk includes but is not limited to:

- » 65 and older
- » Lung disease
- » Heart disease
- » Liver disease
- » Kidney disease
- » Obesity
- » Diabetes
- » Cancer
- » Substance use disorder
- » Immunocompromised

Health care practitioners must communicate information consistent with the EUA Fact Sheet for Patients, Parents, and Caregivers and provide a copy:

PAXLOVID

[fda.gov/media/155051/download](https://www.fda.gov/media/155051/download)

LAGEVRIO

[fda.gov/media/155055/download](https://www.fda.gov/media/155055/download)

FIRST CHOICE: PAXLOVID Oral (Nirmatrelvir/Ritonavir)

for ADULT and PEDIATRIC patients (≥ 12 yo and ≥ 40 kg) under FDA EUA. [FDA Paxlovid Fact Sheet \(for providers\)](#)

- If the patient has no known history of kidney disease
 - Dosing: Take 2 tablets of Nirmatrelvir (150mg) and 1 tablet of Ritonavir (100mg) by mouth twice a day for 5 days
- If the patient has known kidney disease (eGFR ≥ 30 to ≤ 60 mL)
 - Renal Dosing: Take 1 tablet of Nirmatrelvir (150mg) and 1 tablet of Ritonavir (100mg) by mouth twice a day for 5 days
- NOT RECOMMENDED for patients with eGFR < 30 or severe liver disease (Child-Pugh Class C)
- Side effects: distaste/dysgeusia (6%), diarrhea (3%), myalgia (1%), hypertension (1%), hypersensitivity
- [Paxlovid Screening Checklist](#)
- [Check for clinically relevant drug-drug interactions](#)

SECOND CHOICE: LAGEVRIO Oral (Molnupiravir)

for ADULT patients (≥ 18 years old) under FDA EUA. [FDA Fact Sheet Molnupiravir \(for providers\)](#)

- Use **only** when alternative COVID-19 treatments approved or authorized by FDA are not accessible or clinically appropriate
- Dosing: Take 4 tablets (200mg) by mouth every 12 hours for 5 days.
- No dose adjustments needed for renal or hepatic impairment
- Side effects: diarrhea (2%), nausea (1%), dizziness (1%)
- **Warnings and Precautions:**
 - Embryo-Fetal Toxicity – NOT RECOMMENDED for pregnant women or women who may be pregnant. For men or women who are in their reproductive ages, FDA EUA recommends contraception use for 3 months after the last dose of Molnupiravir, since there may be fetal toxicity.
 - Hypersensitivity reactions, including anaphylaxis have been reported. If severe, discontinue Molnupiravir.
 - Bone and Cartilage Toxicity – NOT RECOMMENDED in patients < 18 years old, may affect bone/cartilage growth.

Resources

Hawaii Department of Health - Outpatient Treatments health.hawaii.gov/coronavirusdisease2019/for-clinicians/covid-19-treatment
NIH Info on Paxlovid [covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-](https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-)
NIH Info on Molnupiravir [covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/molnupiravir](https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/molnupiravir)